Non-cystic fibrosis bronchiectasis

McDonnell, MJ; Ward, Chris; Lordan, JL; Rutherford, RM

doi:10.1093/qjmed/hct109

Cited by 24 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of congenital malformations in BE etiology differs between 1% and 13.6% [14][15][16][17][18][19][20] . 1.8% of our cases had congenital malformations (one pulmonary sequestration and one idiopathic congenital BE) (Table I).…”

Section: Discussionmentioning

confidence: 99%

Changing epidemiology of non-cystic fibrosis bronchiectasis

Bahçeci¹,

Karaman²,

Nacaroğlu³

et al. 2016

Turk J Pediatr

View full text Add to dashboard Cite

The etiology of bronchiectasis was detected as; primary ciliary dyskinesia 26.4%, protracted bacterial bronchitis 22.8%, primary immune deficiency 11.8%, bronchiolitis obliterans 8.2%, lung disease secondary to gastro-esophageal reflux 3.7%, foreign body aspiration 2.7%, tuberculosis %2.7, congenital malformation 1.8% and asthma 1.8%, respectively. In 15.4% of cases, etiology was not identified clearly. 91% of the patients were medically treated.In ten years, the frequency of asthma and tuberculosis in etiology had decreased but primary ciliary dyskinesia and primary immune deficiency had increased. Non-cystic fibrosis bronchiectasis can be followed up for a long time with medical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Changing epidemiology of non-cystic fibrosis bronchiectasis

Bahçeci¹,

Karaman²,

Nacaroğlu³

et al. 2016

Turk J Pediatr

View full text Add to dashboard Cite

show abstract

“…Patients with non-CF bronchiectasis suffer from recurrent exacerbations, resulting in the destruction of the airways and reduced quality of life [26]. This meta-analysis presented evidence for a beneficial effect on pulmonary exacerbation with macrolides treatment.…”

Section: Discussionmentioning

confidence: 99%

Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials

Wei

et al. 2015

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to evaluate the clinical benefits and safety of the long-term use of macrolides in patients with non-cystic fibrosis (non-CF) bronchiectasis.MethodsEmbase, Pubmed, the Cochrane Library and Web of Science databases were searched from inception up to March 2014. The primary outcome was the improvement of exacerbations of bronchiectasis. Secondary endpoints included changes of microbiology, lung function, quality of life, sputum volume, adverse events and macrolide resistance.ResultsThe literature search yielded 139 studies, ten of which containing 601 patients were included in this meta-analysis. Macrolides showed a statistically-significant improvement in reducing acute exacerbations per patient during follow-up treatment (RR = 0.55, 95% CI: 0.47, 0.64, P < 0.001), increasing the number of patients free from exacerbations (OR = 2.81, 95% CI: 1.85, 4.26, P < 0.001), and prolonging time to a first exacerbation (HR = 0.38, 95% CI: 0.28, 0.53, P < 0.001). Macrolides maintenance treatment was superior to control with respect to attenuating FEV1 decline (p = 0.02), improving sputum volume (p = 0.009) and SGRQ total scores (p = 0.02), but showed a higher risk of adverse events, especially diarrhea (OR = 5.36; 95% CI: 2.06, 13.98, P = 0.0006). Eradication of pathogens was improved in the macrolide group (OR = 1.76, 95% CI: 0.91, 3.41, P = 0.09), while pathogen resistance caused by macrolides dramatically increased (OR = 16.83, 95% CI: 7.26, 38.99, P < 0.001). The new appearance of a microbiologic profile or participant withdrawal due to adverse events showed no significant differences between the two groups.ConclusionIn patients with non-CF bronchiectasis, macrolide maintenance treatment can effectively reduce frequency of exacerbations, attenuate lung function decline, decrease sputum volume, improve quality of life, but may be accompanied with increased adverse events (especially diarrhea) and pathogen resistance.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-015-0872-5) contains supplementary material, which is available to authorized users.

show abstract

“…Despite the clinical importance of bronchiectasis as a chronic respiratory disease, its true incidence and prevalence are not well known [6,7], and information from the few published reports available varies by country, study period, source and method of research [2e4,8,9]. In general, the data show increasing trends in prevalence, which could be due to improved diagnosis and early detection [2].…”

Section: Introductionmentioning

confidence: 99%